Summary: In a 34-participant randomised study in postmenopausal osteoporosis, denosumab attenuated several teriparatide-related bone-formation responses when the drugs were combined. Findings from 26 evaluable biopsies help explain skeletal mechanisms, but this three-month study did not test fracture prevention.
PICO Summary
| Element | Detail |
|---|---|
| Population | 34 postmenopausal women with osteoporosis, allocated to denosumab (n=9), teriparatide (n=13), or combined treatment (n=12). Twenty-six iliac crest biopsies were suitable for histomorphometry at month 3. |
| Intervention | Combined denosumab 60 mg and teriparatide 20 micrograms during a three-month treatment period; n=12. |
| Comparator | Denosumab 60 mg alone (n=9) and teriparatide 20 micrograms alone (n=13). These were active-treatment comparisons rather than a placebo-controlled trial. |
| Outcomes | At three months, teriparatide monotherapy produced higher histomorphometric bone-formation indices than denosumab or combined therapy. Denosumab attenuated teriparatide-induced formation responses, except for modelling-based formation in the endocortical envelope. The investigators interpreted the combination as preserving bone through remodelling suppression while retaining aspects of new bone formation. Biopsy mechanisms, not fracture incidence, were assessed. The abstract does not provide a single primary between-group effect estimate or quantified adverse-event comparison; no fracture-risk estimate or number needed to treat can be derived from it. |
| Study Design | Randomised, three-arm mechanistic interventional trial with double fluorochrome labelling and a single month-3 iliac crest biopsy. Only 26 of 34 randomised participants had evaluable histomorphometry. This is an original mechanistic RCT, not a clinical review or a fracture-outcomes trial. |
Expert Commentary
I find this study useful for understanding skeletal biology, but not for deciding that combination treatment prevents more fractures. The biopsy findings show that simultaneous antiresorptive and anabolic therapy does not simply add two independent formation responses together. Denosumab suppresses aspects of remodelling while some modelling-based formation persists, offering a plausible explanation for earlier observations of increased bone density. That explanation remains mechanistic rather than a demonstrated clinical outcome. The main limitation is the small, selected biopsy sample: only 26 specimens were evaluable after 34 women were randomised. Short follow-up and tissue measurements cannot establish fracture benefit, durable safety or the best treatment sequence. It would be misleading to turn the histomorphometry results into a numerical reduction in fracture risk. Can I use this with my patients? I would use the study to inform specialist understanding and to explain why changes in bone turnover, density and fracture outcomes are related but not interchangeable. It does not independently justify routine combined treatment or replacement of established osteoporosis pathways. Patients need decisions based on their fracture risk, contraindications and the broader clinical evidence, not a single biopsy endpoint. I would want adequately powered comparative clinical studies before treating this mechanistic explanation as evidence of superior patient benefit.
References
Ramchand SK, Tsai JN, Zhao Y, et al. Comparative bone histomorphometry effects of combined denosumab and teriparatide vs monotherapy in postmenopausal women with osteoporosis: a randomized controlled trial. J Bone Miner Res. 2026;41(5):497-506. doi:10.1093/jbmr/zjaf152. PMID: 41128757.
